

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-16 (cancelled)

17(Currently amended). A method of treating or preventing the rejection of transplanted organs, tissues or cells which comprises administering to a subject in need thereof [[a]] an amino-terminally truncated or extended chemokine receptor antagonist for the RANTS RANTES receptors and a cyclosporin to treat or prevent the rejection of transplanted organs, tissues or cells.

18(Previously presented). The method according to claim 17, wherein the chemokine receptor antagonist and cyclosporin are administered simultaneously.

19(Previously presented). The method according to claim 17, wherein the chemokine receptor antagonist and cyclosporin are administered sequentially or separately.

20(Currently amended). The method according to claim 17, wherein the chemokine receptor antagonist is [[a]] an amino terminally truncated RANTES.

21(Previously presented). The method according to claim 17, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

22(Previously presented). The method according to claim 17, wherein the chemokine receptor antagonist is Met-RANTES.

Claim 23(cancelled)

24(Previously presented). The method according to claim 17, wherein the cyclosporin is cyclosporin A.

25(Previously presented). The method according to claim 24, wherein the chemokine receptor antagonist is Met-RANTES.

26(Previously presented). The method according to claim 25, wherein the rejection treated or prevented is renal allograft transplantation rejection.

27(Currently amended). The method according to claim 24, wherein the chemokine receptor antagonist is [[a]] an amino-terminally truncated RANTES or an amino-terminally extended RANTES.

Claim 28(Cancelled)

29(Previously presented). The method according to claim 17, wherein the rejection treated or prevented is renal allograft transplantation rejection.

30(Previously presented). A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and the combination of a chemokine receptor antagonist for the RANTES receptors and a cyclosporin.

31(Currently amended). The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is [[a]] an amino-terminally truncated RANTES.

32(Previously presented). The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

Appln. No. '09/744,804  
Amdt. dated September 17, 2003  
Reply to Office Action of March 18, 2003

33 (Previously presented). The pharmaceutical according to claim 30, wherein the chemokine receptor antagonist is Met-RANTES.

Claim 34 (cancelled)

35 (Previously presented). The pharmaceutical composition according to claim 30, wherein the cyclosporin is cyclosporin A.

36 (Previously presented). The pharmaceutical composition according to claim 35, wherein the chemokine receptor antagonist is Met-RANTES.

37 (currently amended). The pharmaceutical composition according to claim 34, wherein the chemokine receptor antagonist is [[a]] an amino-terminally truncated RANTES or an amino-terminally extended RANTES.